A Study of LOXO-435 in Patients With Cancer With a Change in a Gene Called FGFR3
Status:
Not yet recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to learn more about the safety, side effects, and
effectiveness of LOXO-435. LOXO-435 may be used to treat cancer of the cells that line the
urinary system and other solid tumor cancers that have a change in a particular gene (known
as the FGFR3 gene). Participation could last up to 30 months (2.5 years) and possibly longer
if the disease does not get worse.